Patent Suit Settlements On The Rise After Failure Of FTC Challenges – Barr
Executive Summary
Settlements of patent litigation cases have become increasingly common because the Federal Trade Commission has been unsuccessful in challenging the validity of some agreements, Barr CEO Bruce Downey said Jan. 5 at the Morgan Stanley Pharmaceutical CEOs Unplugged conference in New York
You may also be interested in...
Generic Exclusivity Triggers May Force Re-evaluation Of Brand/Generic Deals
FDA's consideration of how brand/generic settlements would impact generic exclusivity may be causing firms to reconsider the arrangements
Generic Exclusivity Triggers May Force Re-evaluation Of Brand/Generic Deals
FDA's consideration of how brand/generic settlements would impact generic exclusivity may be causing firms to reconsider the arrangements
Brand/Generic Deals Stay In FTC’s Crosshairs As It Seeks Legal Ammunition
The Federal Trade Commission will not remain complacent as brand and generic companies accelerate the pace and expand the boundaries of settlements, Commissioner Jon Leibowitz said